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study was to compare the efﬁcacy of mirtazapine as PONV prophylaxis with a classic 5HT3 recep-
tor antagonist; ondansetron.
Methods: Eighty female patients with high PONV risk undergoing prophylactic mastectomy with a
standardized anesthetic were randomized to receive either an oral disintegrating tablet (ODT) of
mirtazapine 30 mg (group M) or ondansetron 16 mg (group O) 1 h before surgery. Preoperative
anxiety level was assessed by state and trait anxiety inventory before taking the study drug and
1 h after. Vital sign variables, the incidence of PONV, the use of rescue antiemetic, complete
response, postoperative VAS pain scores, the inverted observer’s assessment of alertness/sedation
scale and side effects were compared.
Results: Mirtazapine premedication reduced preoperative state anxiety inventory scores (P< 0.01)
and the incidence of early nausea and late vomiting (P< 0.05). The percentage of patient having709095/123515195.
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136 H.A.S. Ahmed Omran et al.complete responses during the ﬁrst 24 h after anesthesia was 75% after mirtazapine and 65% after
ondansetron prophylaxis. Anesthetic requirements, postoperative pain, sedation scores, and side
effects were similar between the two groups.
Conclusion: Mirtazapine prophylaxis reduces preoperative anxiety and the incidence of postoper-
ative early nausea and late vomiting compared with ondansetron, without untoward sedative or car-
diovascular effects.
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Women undergoing breast surgery are at particular high risk
for the development of postoperative nausea and vomiting
(PONV) and an incidence of 60–80% in the placebo group
has been reported in many studied [1–3]. Women who elected
to undergo prophylactic mastectomy (surgery to remove one
breast in hopes of preventing or reducing risk of breast cancer
in women who had cancer in the other breast) reported expe-
riencing higher rate of anxiety and depression associated with
developing breast cancer [4].
Mirtazapine is a noradrenergic and speciﬁc serotonergic
antidepressant. It is anxiolytic by virtue of its antagonist of
the 5HT2 receptor, and is strongly sleep inducing. Its antago-
nist at 5HT3 receptor may help to prevent nausea and vomit-
ing [5]. The use of mirtazapine in the management of nausea
and vomiting has been reported in the literature, both for
treatment [6], and premedication [7]. However, the comparison
between mirtazapine as PONV prophylaxis and other 5HT3
receptor blockades have not been studied.
The aim of this study was to compare the efﬁcacy of mirt-
azapine as PONV prophylaxis with ondansetron in women
undergoing prophylactic mastectomy.
2. Methods
After approval of the hospital ethics committee and informed
patient written consent to this double-blind study, 80 ASA
physical status 1 or 2 women undergoing prophylactic mastec-
tomy were enrolled in this study. Patients who were smokers,
or with gastrointestinal disorders, clinically signiﬁcant major
organ disease, or who had received other antidepressant drugs
or an anti-emetic within 48 h before surgery were excluded.
Patients were randomly divided into two equal groups
using computer-generated random numbers with the closed-
sealed envelope, to receive either an oral disintegrating tablet
(ODT) of mirtazapine 30 mg (group M) or ondansetron
16 mg (group O) 1 h before surgery. To insure the study was
blinded, the nurse who prepared or administered the study
drugs was not involved in patient care.
Preoperative anxiety levels using the Spielberger state and
trait anxiety inventory (STAI) were assessed before taking
the study drug, 1 h (immediately before induction of anesthe-
sia), and 24 h after. STAI is a well-established instrument for
the self-reporting of anxiety in the preoperative context [8].
A score for each, ranging between 20 and 80; may then be cal-
culated by an investigator using a scoring key [9] with higher
scores indicate more anxiety.
Patients fasted overnight before their scheduled operation.
No additional premedication was given. On arrival in the oper-
ating room, electrocardiogram, pulse oximetry, noninvasive
arterial blood pressure, and peripheral temperature monitoringwere applied. Baseline vital signs were obtained and subsequent
values were recorded every 5 min throughout surgical proce-
dure. Anesthesia was induced with fentanyl 1.5 lg/kg and pro-
pofol 1.5–2.5 mg/kg until loss of eyelash reﬂex. Tracheal
intubation was facilitated with rocuronuim 0.5 mg/kg. Anesthe-
sia was maintained with isoﬂurane (1–2.5%), nitrous oxide in
40% oxygen and intermittent doses of muscle relaxant if needed
to maintain adequate muscle relaxation throughout the proce-
dure. The respiratory tidal volume was adjusted to keep end-ti-
dal CO2 at 4.8–5.2%. The isoﬂurane concentrationwas adjusted
to keep heart rate and blood pressure within 20% of preinduc-
tion values throughout the anesthesia period. All surgical proce-
dures were completed by the same surgeon. At the end of
surgery, atropine 0.02 mg/kg and neostigmine 0.05 mg/kg were
given IV for antagonism of neuromuscular blockade. Time to
awaken (from the end of anesthesia until the patients opened
their eyes on command) and time to the ﬁrst dose of postopera-
tive analgesiawere recorded. Postoperatively, nalbuphine 20 mg
IMwas prescribed every 4 h or as requested by the patients. The
ward nurses were instructed to omit the four hourly doses if they
considered that the patient was over sedated or pain free (pain
levels below four on visual analog scale; VAS). Postoperative
pain intensity was rated by the patients using a 10-cmVAS, with
0 = no pain and 10 = the worst pain imaginable. The patient’s
level of sedation was assessed using the inverted observer’s
assessment of alertness/sedation (OAA/S) scale [10] with a score
of 1 = awake alert to 5 = asleep, unarousable. The postopera-
tive data (e.g. vital signs, pain, and sedation scale) were collected
every 4 h. The occurrences of early (0–2 h), delayed (2–24 h) and
total (0–24 h) PONV were recorded [11]. Nausea was deﬁned as
a subjectively unpleasant sensation associatedwith awareness of
the urge to vomiting. Vomiting was the forceful expulsion of
gastric contents from the mouth. The severity of nausea was as-
sessed using a verbal numerical rating scale from 0 = no nausea
and 10 = nausea as bad as it could be. For the purpose of data
collection, retching (the same as vomiting but without expulsion
of gastric contents) was considered vomiting. If patients experi-
enced nausea for 30 min, or more than one emetic episode in
15 min, rescue antiemetic treatment consisted of metoclopra-
mide 10 mg IV every 4 h. Complete response was deﬁned as
no PONV or no administration of rescue antiemetic during
24 h after surgery. Duration of hospital stay and incidence of
side effects (headache, dizziness, elevated liver enzymes,
somnolence, or dry mouth) were recorded. Blood samples were
taken from all patients preoperatively and after 1 week postop-
eratively to compare liver enzymes level (SGPT).
2.1. Statistical analysis
Power analysis revealed a sample size of 40 patients per group,
was sufﬁcient to achieve a power of 80% with a error at 0.05
and b at 0.2 to detect a clinically relevant 30% reduction in
Figure 1 Mean ± 95% Cl, state anxiety before, and after 1, 24 h
of premedication by mirtazapine (M) and ondansetron (O).
**P< 0.01.
Effect of premedication with mirtazapine versus 137the total frequency of PONV [12]. Parametric data were ana-
lyzed by Student’s t test; frequencies of nausea, and vomiting
were analyzed by using v2 test or Fisher’s exact test with small
values. The VAS data were analyzed by using the Mann–Whit-
ney’s U test. A value of P< 0.05 was considered statistically
signiﬁcant. Commercial SPSS 11.0 software for window and
Graph pad In Stat version 3.0 were used for data processing.
3. Results
There were no differences in patient demographics, the simpli-
ﬁed risk score by Apfel et al. [13], and operative characteristics;
(duration of anesthesia, propofol induction dose, the concen-
tration of isoﬂurane for maintenance, and recovery time) be-
tween the two groups (Table 1). There was no difference in
mean baseline vital signs values (heart rate, blood pressure,
and Spo2) or in subsequent values during surgery and analge-
sia between the two groups. We found signiﬁcantly lower pre-
operative state-anxiety level in M group at 1 h after
mirtazapam administration compared with group O (Fig 1).
Table 2 demonstrates the incidence of nausea and vomiting
during different observatory periods. The total mean verbal
nausea assessment score was signiﬁcantly lower in the M group
compared with O group during 0–24 h postoperatively
(mean ± SD; 1.9 ± 2.3 versus 3.2 ± 2.1; P< 0.05). The inci-
dence of nausea between groups was statistically signiﬁcant
during early (0–2 h) observation period (P< 0.05). However,
the incidence of vomiting was statistically less during late (2–
24 h) observation period in the M group (P< 0.05). Numbers
of patients with two or more emetic episodes and the require-
ment for rescue antiemetic were signiﬁcantly reduced in M
group versus O group (P< 0.05). The 95% conﬁdence interval
(CI) for total PONV/24 h ranges from 0.3607 to 1.414 (relative
risk = 0.7143).
Postoperative wound pain scores (VAS) at rest are reported
in Table 3. Pain scores were less than 4 in all patients. There
were no statistically signiﬁcant differences in the postoperative
pain scores or in the rescue pain medication between groups.
Also there were no signiﬁcant differences in the mean sedationTable 1 Patient demographics and operative characteristics in mirt
(SD), numbers (n).
Variable Gr
Age (y) 45.
Weight (kg) 65.
Height (cm) 164
ASA status (I:II) 28:
Days since last menstrual cycle (n) 14
Women with no menses (n) 6
Simpliﬁed risk scorea 2.6
State anxiety score 46
Trait anxiety score 48
Duration of operation (min) 110
Propofol dose (mg) 105
Isoﬂurane% maintenance 1.4
Intravenous ﬂuids (ml) 117
Time to awaken (min) 13.
a The simpliﬁed risk score by Apfel and colleagues [13] could be assesse
PONV or motion sickness, and postoperative opioids. If none, one, tw
approximately 10%, 20%, 40%, 60%, and 80%.score between groups. There were no signiﬁcant differences in
incidence of none-emetic postoperative side effects or duration
of hospital stay among the two groups.
4. Discussion
This study showed that administration of ODT of 30 mg mirt-
azapine compared with 16 mg ondansetron, 1 h before opera-
tion in women at high risk undergoing prophylactic
mastectomy, reduced preoperative anxiety and incidence of
postoperative early nausea and late vomiting, without unto-
ward sedative or cardiovascular effects.
In this study, the percentage of patients with no PONV over
ﬁrst 24 h after anesthesia were 75% after mirtazapineazapine M and ondansetron O groups. Data expressed in mean
oup M, n= 40 Group O, n= 40
5 (11.1) 47.9 (9.1)
7 (7.7) 67.9 (6.9)
(3) 161 (3)
12 30:10
(4) 15 (3)
6
(0.5) 2.7 (0.5)
(10) 42 (8)
(11) 44 (7)
(18) 112 (20)
(16) 113 (26)
(0.3) 1.6 (0.5)
8 (481) 967 (390)
5 (2.2) 11.1 (1.6)
d by four risk factors: female gender, non-smoking status, history of
o, three, and four risk factors are present, the risk for PONV is
Table 2 Number of patients (%) with nausea and vomiting in
mirtazapine (group M) and ondansetron (group O), at intervals
0–2, 2–24, 0–24 h after the end of surgery.
Group M,
n= 40
Group O,
n= 40
0–2 h
Nausea 4 (10) 12 (30)*
Vomiting 3 (7.5) 4 (10)
Nausea and vomiting 6 (15) 12 (30)
Rescue antiemetic 2 (5) 7 (17.5)
2–24 h
Nausea 7 (17.5) 12 (30)
Vomiting 1 (2.5) 8 (20)*
Nausea and vomiting 8 (20) 12 (30)
Rescue antiemetic 2 (5) 5 (12.5)
0–24 h
Nausea 8 (20) 12 (30)
Vomiting 4 (10) 8 (20)
Nausea and vomiting 10 (25) 14 (35)
Rescue antiemetic 4 (10) 12 (30)*
Complete response 30 (75) 26 (65)
* P< 0.05.
Table 3 Pain and sedation score, ﬁrst opioids request,
nalbuphine consumption, incidence of side effects, and time
to discharge.
Group M,
n= 40
Group M,
n= 40
VAS
6 h 2.9 ± 1.1 3 ± 0.8
12 h 3.3 ± 0.9 3.5 ± 0.5
18 h 2.5 ± 1.2 3.6 ± 1.2
24 h 2.8 ± 0.2 3.1 ± 1.5
Sedation score
6 h 1.9 ± 0.3 1.5 ± 0.3
12 h 1.7 ± 0.2 1.4 ± 0.2
18 h 1.7 ± 0.4 1.4 ± 0.1
24 h 1.4 ± 0.3 1.3 ± 0.3
First opioids demand (min) 87.8 (17.7) 60.2 (20.5)
Nalbuphine consumption (mg)
At 12 h 34.6 (6.7) 39.3 (4.9)
24 h after surgery 22.1 (4.1) 30.1 (2.3)
Side eﬀects
Headache 3 2
Dizziness – –
Elevated liver enzymes 1 1
Somnolence 6 3
Dry mouth 2 2
Hospital discharge (h) 23.6 (4.3) 28.3 (2.6)
VAS = mean visual analog scale for pain. Sedation score =
assessment by ﬁve points inverted observer’s assessment of alert-
ness/sedation scale [10], with a score of 1 = awake alert to 5 =
asleep, unarousable. Values are mean ± SD, or number of patients.
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age of ondansetron and mirtazapine used is similar to that rec-
ommended for optimal oral dose to prevent PONV. Theoptimal dose of ondansetron to prevent PONV is likely to be
8 mg IV or 16 mg orally as suggested from several multicentre
trials [14]. Dosed orally or intravenously, the mean elimination
half-life of ondansetron is approximately 3 h. There are poten-
tial advantages of using ODT form of ondansetron which dis-
perses rapidly when placed under tongue without taking a drug
with water and absorbed into the circulation more slowly than
IV form, thus providing a longer period of effective blood level
[15]. Blockage of receptors in the chemoreceptor trigger zone
before the arrival of emetic stimuli associated with anesthesia
and surgery provides greater and long acting antiemetic efﬁ-
cacy [16]. The literature contains a few reports on the use of
the ODT form of ondansetron for PONV in adult [17,18].
The incidence of complete response is reported as frequent as
in our work after 16 mg ondansetron tablets [19].
Mirtazapine ODT is rapidly absorbed after oral administra-
tion and peak plasma level with the onset of action is reached
within about 1.6 h. The elimination half-life ranges from 20 to
40 h. The anxiolytic and sleep-improved effects of mirtazapine
are more rapid in onset within 1 h of oral administration; a re-
sult from the blockade of 5HT2 receptors in fasting patients
[20]. Anxiety or mirtazapine independently affects neither the
propofol dose required for unconsciousness nor the anesthetic
requirements and cardiovascular events that follow propofol
induction. The evidence for a link between preoperative anxi-
ety and PONV from previous results remains weak [21,22].
Our results demonstrate that mirtazapine was associated with
less incidence of early nausea with lower grade during 24 h
postoperative period compared with ondansetron prophylaxis.
Quinn et al. [23] survey has demonstrated an association be-
tween pre-operative anxiety and postoperative nausea but
not vomiting. It has also been suggested that nausea and vom-
iting are separate entities and that nausea is not the normal
and inevitable precursor to vomiting [24]. Anxiolytic and
sleep-improved agent as mirtazapine may be beneﬁcial as a
part of prophylactic anti-nausea measures.
The low incidence of early postoperative vomiting in both
groups may have been related to the use of propofol for induc-
tion. Propofol has been alleged to possess direct antiemetic ac-
tion even when administered in sub hypnotic doses [25]. A
previous study has found postoperative opioids to be one of
the main predictors of PONV in the late postoperative period
[26]. In both groups, patients had similar pain scores and used
nearly similar amounts of nalbuphine in the ﬁrst 24 h postop-
eratively. The high incidence of late vomiting after ondanse-
tron compared with mirtazapine premedication in our study
setting might have related to short half life of ondansetron
and to the fact that nalbuphine-induced vomiting can last for
a much longer periods. A wide individual variation in sensitiv-
ity to narcotics could be another explanation for this.
However, there are certain limitations in this study. First,
group sizes with more patients may be required to demonstrate
statistically signiﬁcant reduction in the incidence of nausea and
vomiting in both early and late observation periods in the
treatment groups. Second, placebo control group was not used
as there is a reported evidence of high risk of PONV among
female patients undergoing breast surgery for long duration.
It is unethical to use placebo tablet in this trial. Third, 5HT3
antagonists with short duration of action were used in compar-
ison with long acting mirtazapine. Dosed orally or intrave-
nously, the mean elimination half-life of tropisetron is 8 h
[27]. Ondansetron, a 5HT3 antagonist, is the ‘‘gold standard’’
Effect of premedication with mirtazapine versus 139antiemetic because of its safety and efﬁcacy compared with
alternatives. Fourth, no control was used for the issue of post-
operative opioids administration. Anderson et al. [28] showed
an almost linear relation between the dose of postoperative
opioids and the incidence of vomiting. It appears to be in
the best interest of patients in this study to use less emetogenic
alternatives rather than opioids for postoperative analgesia,
e.g. local anesthesia, as regional blockade or as wound inﬁltra-
tion, paracetamol, and non-steroidal anti-inﬂammatory agents
[29].
In conclusion, this study showed that premedication with
ODT of mirtazapine 30 mg, versus ondansetron 16 mg may re-
duce the level of preoperative anxiety and the incidence of
early nausea and late vomiting in high-risk female patients
undergoing prophylactic mastectomy under general
anesthesia.
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